Michael J. Detke

Affiliations: 
MedAvante, Hamilton Township, NJ, United States 
Area:
Drug development
Google:
"Michael Detke"
Mean distance: 16.35 (cluster 19)
 

Parents

Sign in to add mentor
Irwin Lucki grad student 1992-1996 Penn
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kiluk BD, Carroll KM, Duhig A, et al. (2015) Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug and Alcohol Dependence
Williams JB, Kobak KA, Giller E, et al. (2015) Comparison of Site-Based Versus Central Ratings in a Study of Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology
Shen JH, Zhao Y, Rosenzweig-Lipson S, et al. (2014) A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research. 53: 14-22
Chappell JC, Eisenhofer G, Owens MJ, et al. (2014) Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects. Journal of Clinical Psychopharmacology. 34: 9-16
Potter WZ, Mallinckrodt CH, Detke MJ. (2014) Controlling placebo response in drug development: Lessons learned from psychopharmacology Pharmaceutical Medicine. 28: 53-65
Chappell JC, Kovacs R, Haber H, et al. (2013) Evaluation of the effects of duloxetine and escitalopram on 24-hour heart rate variability: A mechanistic study using heart rate variability as a pharmacodynamic measure Journal of Clinical Psychopharmacology. 33: 236-239
Skljarevski V, Desaiah D, Liu-Seifert H, et al. (2010) Efficacy and safety of duloxetine in patients with chronic low back pain. Spine. 35: E578-85
Mease PJ, Russell IJ, Kajdasz DK, et al. (2010) Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Seminars in Arthritis and Rheumatism. 39: 454-64
Mallinckrodt CH, Detke MJ, Prucka WR, et al. (2010) Considerations for using positive controls in phase 2 clinical trials of central nervous system disorders Drug Information Journal. 44: 431-441
Mallinckrodt CH, Detke MJ, Prucka WR, et al. (2010) Design archetypes for phase 2 clinical trials in central nervous system disorders Drug Information Journal. 44: 421-430
See more...